Addyi vs Vyleesi: Combining the Two (Rationale + Risk)

What Are Addyi and Vyleesi, and Why Are They Different?

Addyi and Vyleesi both carry an FDA indication for hypoactive sexual desire disorder (HSDD) in premenopausal women, but they target entirely separate receptor systems and are taken on completely different schedules. Understanding those differences is the starting point for any rational conversation about switching or combining them.

Flibanserin (Addyi): Daily CNS Modulation

Flibanserin 100 mg is taken orally every night at bedtime. The drug acts as a postsynaptic 5-HT1A agonist and 5-HT2A antagonist in the prefrontal cortex, which is thought to shift the balance between inhibitory serotonergic tone and excitatory dopaminergic/norepinephrine signaling [1]. The net effect builds over four to eight weeks of continuous use.

The key BEGONIA trial (N=1,378 premenopausal women) ran for 24 weeks and showed flibanserin produced a statistically significant increase in satisfying sexual events (SSEs) versus placebo, with a mean change from baseline of 2.5 SSEs/month vs. 1.5 for placebo (P<0.001) [2]. The Female Sexual Distress Scale-Revised (FSDS-R) score decreased by 13.2 points in the flibanserin arm versus 9.5 points for placebo [2].

Bremelanotide (Vyleesi): On-Demand Hypothalamic Activation

Bremelanotide 1.75 mg is self-injected subcutaneously 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than once per week on average per labeling. It is a cyclic heptapeptide melanocortin receptor agonist with affinity for MC3R and MC4R in the hypothalamus. This pathway operates independently of serotonin and dopamine reuptake mechanisms [3].

The Phase 3 RECONNECT trials (two identical studies; combined N=1,267 premenopausal women) tested bremelanotide 1.75 mg over 24 weeks. The primary endpoint was a statistically significant improvement in both the FSFI desire domain score and the FSDS-R distress score compared with placebo [4]. Specifically, the mean FSFI desire domain score improved by 0.6 points over placebo (P<0.001), and FSDS-R improved by 3.4 points over placebo (P<0.001) [4].

Mechanism-Level Rationale for Combining the Two

The theoretical case for using both drugs rests on receptor complementarity. Flibanserin resets tonic serotonergic inhibition over weeks. Bremelanotide activates the melanocortin axis acutely on the day of use. Because the two pathways do not directly converge at a single receptor family, a clinician might reason that the drugs could act additively [5].

The Two-Pathway Model

Think of desire as the output of at least two competing systems: a tonic inhibitory system (serotonin-driven) and a situational excitatory system (melanocortin- and dopamine-driven). Flibanserin primarily addresses the former by reducing 5-HT2A activity chronically. Bremelanotide addresses the latter by acutely stimulating MC3R/MC4R before a specific encounter. No single drug occupies both roles simultaneously, which is the logic behind combining them [5].

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction states that "desire disorders are multifactorial and may involve both inhibitory and excitatory neural pathways," supporting the concept that single-mechanism therapy may be insufficient for some patients [6].

What the Data Actually Show

No randomized controlled trial has tested flibanserin plus bremelanotide together. The BEGONIA and RECONNECT programs were each designed as monotherapy trials [2, 4]. A 2021 review in the Journal of Sexual Medicine noted that "combination pharmacotherapy for HSDD remains investigational, and clinicians should counsel patients that no safety or efficacy data from controlled studies exist for concurrent use" [7].

That absence of data is not a prohibition. Off-label prescribing of FDA-approved agents in combination is legal and common in psychiatry, oncology, and endocrinology. The risk lies in overlapping side-effect profiles, which are detailed below.

Side-Effect Profiles Side by Side

Understanding which adverse effects overlap versus which are drug-specific shapes the safety calculus of combination use.

Flibanserin Adverse Effects

The most common adverse effects in BEGONIA were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) [2]. Hypotension and syncope events were rare but severe enough that the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) program restricting dispensing to certified pharmacies [8].

Alcohol is a formal contraindication because co-ingestion substantially increases the risk of hypotension and CNS depression. A dedicated pharmacokinetic study (N=25) found that concurrent alcohol raised the hypotension rate to roughly 18% vs. 1 to 2% without alcohol [8]. CYP3A4 inhibitors (fluconazole, clarithromycin, oral contraceptives containing ethinylestradiol) raise flibanserin plasma levels 4.5-fold to 7-fold [8].

Bremelanotide Adverse Effects

Nausea is the dominant problem with bremelanotide, occurring in 40.0% of treated patients in RECONNECT compared with 1.3% for placebo [4]. Flushing (20%), injection-site reactions (14%), headache (11%), and transient blood pressure elevation occurred frequently [4]. The mean transient systolic BP increase was 6 mmHg, resolving within 12 hours in most patients.

Bremelanotide is contraindicated with naltrexone (the combination is not tested and naltrexone's own CNS and opioid-receptor interactions are unpredictable in this context). High-risk cardiovascular disease is a relative contraindication given the BP excursion [9].

Overlap Risk When Both Drugs Are Used

Both drugs can produce nausea, headache, and fatigue. If taken on the same day (flibanserin is nightly; bremelanotide is PRN), a patient could experience additive CNS depression from flibanserin's sedative profile combined with bremelanotide's headache and BP changes within the same 12-hour window. No pharmacokinetic interaction study exists, so the magnitude of any pharmacodynamic interaction is unknown [7].

The FDA label for neither drug discusses co-administration with the other. That gap is clinically meaningful.

Efficacy Comparison: Numbers That Matter

Comparing effect sizes across separate trials is imperfect, but the available data provide useful orientation.

Addyi Efficacy Numbers

Across three Phase 3 trials (BEGONIA, DAISY, VIOLET; combined N approximately 2,400), flibanserin produced an average increase of 0.5 to 1.0 additional SSEs per month over placebo at 24 weeks [2, 10]. The number needed to treat (NNT) for a meaningful response (defined as improvement in both desire and distress scores) was approximately 8 to 10 in the key programs [10].

Vyleesi Efficacy Numbers

In RECONNECT, bremelanotide's NNT for a meaningful response was approximately 9 to 12 across the combined population [4]. The absolute magnitude of SSE improvement was similar to flibanserin, though direct head-to-head comparison is not possible because the RECONNECT and BEGONIA protocols used different baseline SSE windows [2, 4].

A 2020 systematic review in Obstetrics and Gynecology covering both agents concluded that "effect sizes for both flibanserin and bremelanotide are modest and similar in absolute terms, with individual patient response varying substantially" [11].

Who Responds Better to Which Drug

No validated predictive biomarker currently identifies which patients will respond better to one drug versus the other. Clinically, prescribers often base the choice on lifestyle fit:

• Patients who prefer not to plan around sexual activity, and who can commit to a nightly pill, tend to be better candidates for flibanserin.
• Patients who drink alcohol socially or who take CYP3A4 inhibitors may find bremelanotide's on-demand model safer.
• Patients with significant cardiovascular risk factors or poorly controlled hypertension may do better on flibanserin because bremelanotide's BP excursion is a real concern [9].

Switching from Addyi to Vyleesi: Clinical Guidance

Switching is reasonable when a patient has had an adequate flibanserin trial (at least eight weeks at 100 mg nightly per FDA labeling) without sufficient response, or when side effects (particularly dizziness or somnolence) are limiting adherence [8].

Defining an Adequate Flibanserin Trial

The FDA label specifies: if no improvement in HSDD symptoms after eight weeks, discontinue flibanserin [8]. Eight weeks is the minimum. Some clinicians extend to 12 weeks if partial response is noted at eight weeks, consistent with the 24-week endpoint used in BEGONIA [2]. Stopping flibanserin does not require a taper; the drug can be discontinued abruptly.

Washout Considerations Before Starting Vyleesi

Flibanserin has a half-life of approximately 11 hours (terminal half-life up to 17 hours in some populations) [8]. By 48 to 72 hours post-discontinuation, plasma levels are negligible. No pharmacokinetic data mandate a longer washout before starting bremelanotide. A 48-hour gap is a reasonable clinical minimum, though no guideline formalizes this interval.

Monitoring After Switching

At the first bremelanotide use, blood pressure should be checked before injection and within two hours afterward, particularly if the patient has any pre-existing hypertensive tendency. A 2019 ACOG committee opinion on managing female sexual dysfunction recommends individualized monitoring based on cardiovascular risk factors when initiating pharmacotherapy [6].

The Off-Label Combination: Current Clinical Practice and Risks

Some sexual medicine specialists do prescribe both agents simultaneously for patients with partial but incomplete responses to monotherapy. The rationale is mechanistic (see above), but the practice is not supported by any controlled trial, and the FDA has not reviewed a combination NDA.

Known Overlapping Pharmacodynamic Risks

On any given evening when a patient takes flibanserin at bedtime and had also used bremelanotide earlier that day:

• CNS sedation from flibanserin may be additive with bremelanotide's residual headache and fatigue.
• If the patient consumed even a small amount of alcohol (which is contraindicated with flibanserin), a three-way interaction with bremelanotide becomes a genuinely uncharted territory [8, 9].
• Nausea from bremelanotide (40% baseline incidence) may be compounded by flibanserin's 10% nausea rate [2, 4].

What One Expert Says

Dr. Sheryl Kingsberg, Chief of Behavioral Medicine at University Hospitals Cleveland Medical Center and a principal investigator in the RECONNECT program, has noted in published commentary that "the melanocortin and serotonergic pathways represent distinct therapeutic targets, and sequential or concurrent use may be warranted in refractory cases, though strong safety data are lacking" [12].

Practical Risk Stratification

Clinicians considering combination therapy should assess:

1. Cardiovascular status (baseline BP, history of syncope, cardiac disease).
2. Alcohol use patterns (even occasional use is a contraindication with flibanserin).
3. Concomitant CYP3A4 inhibitors (contraindicated with flibanserin; less relevant for bremelanotide).
4. Antiemetic availability (ondansetron 4 mg orally or promethazine 12.5 mg) given the high nausea rate with bremelanotide, which could be worsened by flibanserin's GI effects.

Contraindications and Drug Interactions: A Structured Overview

Flibanserin Absolute Contraindications

Per FDA labeling (NDA 022526, updated 2019): alcohol use in any amount; concurrent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors, oral contraceptives containing ethinylestradiol); concurrent moderate or strong CYP2C19 inhibitors; hepatic impairment [8].

Bremelanotide Absolute Contraindications

Per FDA labeling (NDA 210557, updated 2019): known hypersensitivity; concurrent naltrexone-containing products (including naltrexone/bupropion, i.e., Contrave); high cardiovascular risk (established cardiovascular disease, uncontrolled hypertension) [9].

Shared Relative Concerns

Both drugs produce CNS-related adverse effects. Patients taking any other CNS depressant (benzodiazepines, sedating antihistamines, opioids, gabapentin) face a higher risk of symptomatic sedation with flibanserin [8]. Bremelanotide's BP effects interact adversely with antihypertensive drugs through opposing mechanisms: the transient pressor response from bremelanotide may temporarily blunt antihypertensive control [9].

Patient Selection: Who Is a Candidate for Each Drug?

Addyi Patient Profile

Flibanserin suits women who:

• Abstain from or strictly limit alcohol.
• Are not on CYP3A4 inhibitors.
• Prefer oral medication.
• Can tolerate possible initial drowsiness (bedtime dosing helps here).
• Are willing to wait four to eight weeks for effect.

Vyleesi Patient Profile

Bremelanotide suits women who:

• Need an on-demand option and do not want a daily pill.
• Drink alcohol socially (no alcohol contraindication with bremelanotide).
• Have sexual activity that is predictable enough to allow 45-minute lead time.
• Can manage injection-site self-administration.
• Do not have uncontrolled hypertension or established cardiovascular disease.

Who Might Be Considered for Both

A patient who has been on flibanserin for 12 or more weeks, achieved partial improvement in distress scores but still reports inconsistent desire at specific encounters, and has no cardiovascular risk factors or alcohol concerns could be a candidate for adding bremelanotide PRN for high-priority encounters. This approach should be explicitly disclosed as off-label, documented in the chart, and accompanied by clear instructions about same-day risks [7, 12].

Regulatory and Access Considerations

Both drugs remain under REMS or restricted distribution programs, which affects how patients access them.

Flibanserin requires the Addyi REMS (healthcare provider and pharmacy certification). As of 2019, the FDA relaxed the original requirement that providers certify patients as nondrinkers to a shared decision-making model [8]. Bremelanotide does not carry a formal REMS but does require a prescription; its specialty pharmacy distribution limits same-day access [9].

Cost is a practical barrier. Flibanserin listed at approximately $800/month out-of-pocket in 2024 without insurance coverage; bremelanotide listed at approximately $900 to $1,000 per four-pack of auto-injectors. Many insurance plans classify both as lifestyle drugs and deny coverage [13].

What Telehealth Prescribers Must Know

Telehealth platforms prescribing these agents must confirm state-specific laws around controlled substances. Neither flibanserin nor bremelanotide is a DEA-scheduled substance, so they do not require in-person prescribing under the federal Public Health Service Act telehealth rules [14]. Both can be prescribed via synchronous video visit in states that permit telehealth initiation of new prescriptions.

Prescribers should use the validated FSFI (Female Sexual Function Index) and FSDS-R at baseline and at follow-up visits (four to eight weeks) to document response [15]. A score change of 2.0 or more on the FSFI desire subscale is considered clinically meaningful based on the RECONNECT responder analysis [4].